RT info:eu-repo/semantics/article
T1 A dangerous liaison: Leptin and sPLA2-IIA join forces to induce proliferation and migration of astrocytoma cells
A1 Martín Martín, Rubén
A1 Córdova, Claudia
A1 Gutierrez Miranda, Beatriz Rosa
A1 Hernández Garrido, Marita
A1 Nieto Callejo, María Luisa
K1 Leptin
K1 Leptina
K1 sPLA2-IIA
K1 Astrocytoma cells
K1 Astrocitomas
AB Glioblastoma, the most aggressive type of primary brain tumour, shows worse prognosis linked to diabetes or obesity persistence. These pathologies are chronic inflammatory conditions characterized by altered profiles of inflammatory mediators, including leptin and secreted phospholipase A2-IIA (sPLA2-IIA). Both proteins, in turn, display diverse pro-cancer properties in different cell types, including astrocytes. Herein, to understand the underlying relationship between obesity and brain tumors, we investigated the effect of leptin, alone or in combination with sPLA2-IIA on astrocytoma cell functions. sPLA2-IIA induced up-regulation of leptin receptors in 1321N1 human astrocytoma cells. Leptin, as well as sPLA2-IIA, increased growth and migration in these cells, through activation/phosphorylation of key proteins of survival cascades. Leptin, at concentrations with minimal or no activating effects on astrocytoma cells, enhanced growth and migration promoted by low doses of sPLA2-IIA. sPLA2-IIA alone induced a transient phosphorylation pattern in the Src/ERK/Akt/mTOR/p70S6K/rS6 pathway through EGFR transactivation, and co-addition of leptin resulted in a sustained phosphorylation of these signaling regulators. Mechanistically, EGFR transactivation and tyrosine- and serine/threonine-protein phosphatases revealed a key role in this leptin-sPLA2-IIA cross-talk. This cooperative partnership between both proteins was also found in primary astrocytes. These findings thus indicate that the adipokine leptin, by increasing the susceptibility of cells to inflammatory mediators, could contribute to worsen the prognosis of tumoral and neurodegenerative processes, being a potential mediator of some obesity-related medical complication.
PB PLOS ONE
SN 1932-6203
YR 2017
FD 2017
LK https://uvadoc.uva.es/handle/10324/46971
UL https://uvadoc.uva.es/handle/10324/46971
LA eng
NO PLoS ONE, 2017, vol. 12, n. 3. p. 1- 22
NO Producción Científica
DS UVaDOC
RD 27-abr-2024